type here...

Health Care

Americans spend significantly more on health care than any other country. Why? Answers to this question range from hospital monopolies to perverse incentives to opaque pricing to medical licensing to pharmaceutical firms abusing IP practices to “creeping consolidation.” Why is the US health care system so broken? And what can antirust do about it? Catch-up on our coverage of antitrust and the US health care system.

Antitrust and Competition

Antitrust Enforcement Is Not Enough to Address Anticompetitive Conduct in Pharmaceutical Markets. Market-Oriented Legal Reform is Needed.

Alden Abbott
Federal antitrust enforcement has been robust and effective in promoting prescription drug market competition and thereby enhancing consumer welfare. Antitrust enforcement in...
Read more
Antitrust and Competition

Competition Problems in Prescription Drug Market

Michael Kades
Although not the sole cause of high prescription drug costs, abusive practices that distort competition contribute to the problem. Too many companies...
Read more
Antitrust and Competition

Why the FTC Should Consider Size in Drug Mergers

Patricia M. Danzon, Michael A. Carrier
Large pharmaceutical firms retain their dominance through size-related advantages in three areas: contracting, marketing and selling, and financing. When reviewing pharmaceutical mergers,...
Read more
Antitrust and Competition

The Covid-19 Pandemic Should Not Delay Actions to Prevent Anticompetitive Consolidation in US Health Care Markets

Leemore Dafny
Harvard Business School professor Leemore Dafny lays out potential reforms to assist agencies in halting anticompetitive acquisitions and practices, and to preserve...
Read more
Antitrust and Competition

Invigorating Competition in Health Care Markets: Is Rate Regulation Needed?

Tim Greaney
It now appears that market concentration may be the leading cause of America’s health care cost crisis. If the United States is...
Read more
Antitrust and Competition

Opening the Black Box: The Hidden Costs of Data-Driven Mergers in Health Care

Theodosia Stavroulaki
Vertical data-driven mergers between health insurers and drug suppliers may facilitate health insurers’ efforts to discriminate against vulnerable populations, leaving them without...
Read more
Antitrust and Competition

How the FTC Protected the Market Power of Pharmacy Benefit Managers

Stacy Mitchell, Zach Freed
Pharmacy Benefit Managers (PBMs) were established in the 1960s to control drug costs but have since morphed into one of the most...
Read more
Antitrust and Competition

What Is the Price of a Prescription Drug?

Robin Feldman
Due to lack of transparency and mystery rebates, which are considered trade secrets, figuring out the price of a prescription drug is...
Read more
Covid-19

“The Way Insurance Companies Have Rigged Our Health Care System, They’re Probably Going to Emerge as Financial Winners from This”

Asher Schechter
Author and former health insurance executive Wendell Potter explains to ProMarket why the employer-based health care system in the US is “collapsing” and why health...
Read more
Antitrust and Competition

The Amazon of Health Care: How CVS Is Evolving From a Drug Store Chain into a Tech Platform

Matt Stoller
CVS is built on a dominant chain of drug stores, but it is now trying to turn itself into a "uniquely powerful platform" for...
Read more
12Page 1 of 2

Latest news

Development

Mobile Internet Is Changing Employment in Developing Countries, but Not Always as Expected

Pinelopi Koujianou Goldberg, Gaurav Chiplunkar
Scholars and policymakers have put much faith into the prospect of internet connectivity catalyzing development in low- and middle-income countries. In new...
Read more
Fiscal Policy

Biden’s Second-Best Economic Agenda

Walter Frick
Efficiency is out and political economy is in. But what does that imply about making good policy?
Read more
Monetary Policy

The Fed and Bank Failures

Raghuram Rajan, Viral V Acharya
Viral Acharya and Raghuram Rajan explain how quantitative easing contributed to the problems underlying the recent bank failures such as that of...
Read more
Antitrust and Competition

Self-Preferencing Theories Need To Account for Exploitative Abuse

Patrice Bougette, Oliver Budzinski, Frédéric Marty
Patrice Bougette, Oliver Budzinski, and Frédéric Marty argue in their research that antitrust authorities on both sides of the Atlantic must take...
Read more
Antitrust and Competition

Startup Acquisitions Have Undecided Effects on Innovation and Economic Growth

Christian Fons-Rosen, Pau Roldan-Blanco, Tom Schmitz
Startups are a major driver of innovation, but many startups are acquired by large incumbents. Do these acquisitions stifle innovation or promote...
Read more
ESG & Corporate Governance

History Shows that Voluntary ESG Standards Lead to a More Focused ESG Disclosure

Ethan Rouen, Kunal Sachdeva, Aaron Yoon
In recent years, ESG reports have become more common for publicly traded companies. However, critics have found the information they provide to...
Read more
Regulation

Letters that Matter: How Interest Groups Shape Financial Legislation

Renée Adams, Thomas Mosk
Members of Congress are inundated with an avalanche of correspondence on a daily basis. But what persuades them to heed the call?...
Read more
View All

ProMarket is dedicated to discussing how competition tends to be subverted by special interests. The posts represent the opinions of their writers, not necessarily those of the University of Chicago, the Booth School of Business, or its faculty. For more information, please visit ProMarket Policy.

About Us

Categories

What we are readingAntitrust and CompetitionNewsRegulatory CaptureMediaRent seeking